Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Disease and Half-Life Extension Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FcRn/FCGRT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FcRn (FCGRT/B2M Heterodimer) ECD Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View FcRn/FCGRT Products |
| Gene Delivery | FcRn/FCGRT Lentivirus Full-length ORF for stable cell lines. Preserves native membrane conformation. |
View FcRn/FCGRT Products |
| Benchmark Ab | Anti-FcRn (Sequence of Efgartigimod / Nipocalimab) Recombinant positive control for blocking and internalization assays. |
View FcRn/FCGRT Products |
| Validator | FCGRT siRNA Set For knockdown verification and specificity controls. |
View FcRn/FCGRT Products |
| Related Target A | B2M (Beta-2-microglobulin) Essential heterodimer subunit required for functional FcRn folding and cell surface expression. |
View B2M Products |
| Related Target B | ALB (Albumin) Alternative endogenous ligand; used for selectivity screening to avoid albumin depletion. |
View Albumin Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| pH-Dependent IgG Binding (pH 6.0 binding / pH 7.4 release) | Human FCGRT-B2M Heterodimer (HEK293 expressed) with validated pH-dependent binding; Sequence Verified. |
| Cross-species Translation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog proteins available (>95% purity, theoretical MW confirmed). |
| Dual Ligand Competition (IgG vs Albumin) | High-purity FCGRT-B2M complex validated for competitive binding assays with both IgG Fc and Albumin. |
| Heterodimer Stability & Glycosylation | Co-expressed complex with native glycosylation, Endotoxin <1EU/ug. |
| Lack of Positive Controls | Sequence-verified clinical benchmark antibodies (biosimilars) available for assay calibration. |
| Cell Line Validation & Endosomal Routing | High-titer Lentivirus for stable expression and intracellular trafficking studies. |
Live FcRn/FCGRT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FcRn therapeutics is intensifying, with major players expanding from rare orphan indications into mainstream autoimmune diseases. The mechanism—accelerating clearance of pathogenic IgG by blocking FcRn—has proven highly efficacious. First-generation therapies (Efgartigimod, Rozanolixizumab) have established the standard of care in generalized myasthenia gravis (gMG). The next wave targets chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), pemphigus vulgaris, thyroid eye disease, and rheumatoid arthritis. The competitive landscape is bifurcating between high-affinity monoclonal antibodies for rapid IgG clearance and engineered Fc-fusion fragments optimized for pH-dependent release. Key trends include a shift from intravenous to subcutaneous delivery, minimizing albumin interference, and enhancing half-life extension platforms for broader biologic pipelines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-FcRn Monoclonal Antibody | UCB (Rozanolixizumab), J&J (Nipocalimab), Immunovant (Batoclimab / IMVT-1402) | gMG, CIDP, ITP, Thyroid Eye Disease | High-affinity blocking assay (need Human/Cyno FCGRT-B2M complex for SPR/BLI) |
| Fc-Fusion Antibody Fragment | argenx (Efgartigimod) | gMG, PV, CIDP | pH-dependent release kinetics (need validated pH 6.0 vs 7.4 binding) |
| Small Molecule Inhibitor | Several preclinical programs | Autoimmune diseases | Orthosteric binding displacement assay (need pure FCGRT ECD) |
| FcRn Agonist (Half-life Extension) | Various biotech (Engineered IgG) | Protein therapeutics (broad) | Binding enhancement assay (need wild-type vs mutant FCGRT comparison) |
Molecular Mechanism & Structural Biology
FcRn (neonatal Fc receptor) is a heterodimer encoded by FCGRT (heavy chain) and B2M (light chain). It binds IgG and albumin in a pH-dependent manner (acidic pH 6.0 in endosomes for binding, neutral pH 7.4 for release). This recycling pathway maintains serum IgG and albumin half-life, and dysfunction leads to autoimmune or half-life extension opportunities. FcRn is a class I MHC-like molecule with an Ig-like C1-type domain in FCGRT (UniProt P55899 evidence).